Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 November 2020 | Story Dr Nitha Ramnath

In this webinar, Prof Brownhilder Neneh of the University of the Free State, and Christopher Rothmann, co-founder of LiquidCulture, discuss the intersection between the two fields of science and entrepreneurship, and entrepreneurship and the university curriculum from an interdisciplinary perspective. The webinar will provide insight into entrepreneurship at universities, particularly the UFS, advancing entrepreneurship development and entrepreneurship-related programmes that are student focused, and illustrate the critical role that entrepreneurship plays in the lives of students.

This webinar is part of a series of three webinars on Interdisciplinarity that is presented from November to December 2020 via Microsoft Teams for a duration of 45 minutes each. The webinar topics in the series explore the intersection between Neuroscience and Music, between Science and Entrepreneurship, and between Science and Visual Arts.  

Date: Tuesday 24 November 2020
Topic: The intersection between science and entrepreneurship 
Time: 13:00-13:45 (SAST)
RSVP: Alicia Pienaar, pienaaran1@ufs.ac.za by 23 November 2020 
Platform: Microsoft Teams

Introduction and welcome

Prof Corli Witthuhn 
Vice-Rector: Research at the University of the Free State 


Presenters

Prof Brownhilder Neneh 

Prof Neneh is Associate Professor and Academic Chair (HOD) in the Department of Business Management at the University of the Free State.  She is an NRF-rated researcher in the field of entrepreneurship and small business development. Her research is primarily based in the field of entrepreneurship, where she looks at different aspects of a business venture – from business gestation activities to performance, growth, and exit.  She also focuses on some niche areas in entrepreneurship, such as women and student entrepreneurship. She was a 2019 winner of the Emerald Literati Awards in the category Outstanding and Highly Commended papers. 

Christopher Rothmann – Co-founder of LiquidCulture

Liquid Culture (LC) was started by Christopher Rothmann and Dr Errol Cason in the UFS Department of Microbial, Biochemical and Food Biotechnology in 2018. They produce yeast in its purest liquid form. LC is the only company in Africa to do so. Their yeast is mainly used by breweries for the fermentation of beer and they have since also branched out to the baking and distillery industries. Christopher was awarded the joint runner-up position in the Existing Tech Business category of the 2019 Entrepreneurship Intervarsity.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept